BALTIMORE (AFX) - Osiris Therapeutics Inc., a biopharmaceutical company, on Monday said it amended its registration statement to specify it will offer 3.5 million shares at $11 to $13 in its initial public offering.
Osiris said Jefferies & Co. is the lead bookrunning manager and Lazard Capital Markets is acting as co-lead manager.
The company expects to make available to the underwriters up to an additional 525,000 shares for over-allotments.
Osiris's Osteocel product, used to regenerate bone, is the only commercially available product containing stem cells in the United States.
The company expects to trade under the 'OSIR' symbol on the Nasdaq.
Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.